On September 17, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, reported that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Panna Sharma, Founder and CEO of Open-Medicine AI, will lead the session, which is intended for investors, biopharma and academic collaborators, and prospective partners. The webinar will explain how OMAI is extending the AI co-scientist approach first commercialized in withZeta.ai — launched in April 2026 and focused on rare and aggressive cancers — into additional disease categories, new therapeutic modalities, and the downstream development challenges that consume most of the time and cost between a validated target and a treated patient. A question-and-answer period will follow the presentation.
Built Where the Problems Are
Most AI for drug discovery is built at a distance from drug development. Open-Medicine AI was built inside it. Its co-scientists were developed within Lantern’s own clinical programs — with the same data, constraints, regulatory requirements, and decision points that determine whether a molecule reaches patients — and were first put to work in withZeta.ai, which launched in April 2026 and is in use across rare and aggressive cancers.
The drug discovery and development markets are already moving in this direction. Independent analysts estimate the AI in drug discovery market at approximately $2.9 billion in 2026, growing to $13.8 billion by 2033.1 Additionally, analysts have noted that AI deployments in pharma are moving from pilots to enterprise-scale, agentic systems.2, 3
The result is a platform that does more than propose candidates. It reasons across the full development pathway — target and biomarker selection, compound and modality design, translational analysis, trial design, and regulatory strategy — in which the agents carry the operating knowledge of the scientists and clinicians who built them. The webinar will present:
The platform: the multi-agentic architecture behind Open-Medicine AI, how its co-scientists coordinate across the development pathway, and what distinguishes an agent trained inside active clinical programs from a general-purpose model
The roadmap: the next generation of co-scientists beyond rare cancers, the disease categories and therapeutic modalities being prioritized, and the downstream development challenges — trial design, patient selection, regulatory and translational work — that the platform is being extended to address
The business model: how Open-Medicine AI intends to generate revenue through subscription access and enterprise licensing, and how it works with biopharma companies, research institutions, service providers, and drug developers
The value proposition: where the platform is designed to remove time, cost, and failure from the path between a validated target and a treated patient, and how that is measured
Why now: why an AI platform for therapeutic development is best built by a company that develops therapeutics, and what that means for Lantern Pharma shareholders and for the researchers, developers, and technology partners who will use it
"We did not set out to build an AI company. We set out to get cancer drugs to patients faster and with less capital, and we built the tools we needed to do that because they did not exist. withZeta.ai is what came out of that work, and it is now running inside real programs with real regulatory and clinical consequences. Open-Medicine AI takes that architecture beyond rare cancers and beyond Lantern — into new disease categories, new modalities, and the downstream parts of development where most of the time, cost, and failure live. On September 23 we will show what we have built, how it will be adopted by industry professionals and service providers, and what the development roadmap for the platform and business could look like. We believe that the most useful AI for therapeutic development will come from the people who have actually developed therapeutics and taken them into meaningful trials for the benefit of patients, and done so with a data-driven, time- and cost-conscious mentality."
— Panna Sharma, President and Chief Executive Officer, Lantern Pharma
Webinar Details
Title
Open-Medicine AI: A Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition
Date
Wednesday, September 23, 2026
Time
12:30 PM Eastern / 9:30 AM Pacific
Presenter
Panna Sharma, President and CEO, Lantern Pharma; Founder and CEO, Open-Medicine AI
Format
45 minutes — a 30–35 minute presentation followed by live Q&A; questions may be submitted in advance to [email protected]
Registration
Replay
A recording will be available on the Investors section of www.lanternpharma.com following the event
(Press release, Lantern Pharma, SEP 17, 2026, View Source;a-Multi-Agentic-Platform-for-End-to-End-Therapeutic-Development–Business-Model-Roadmap-and-Value-Proposition-on-September-23/default.aspx [SID1234670926])